Irreversible binding and metabolism of propranolol by human liver microsomes—Relationship to polymorphic oxidation

This publication has 28 references indexed in Scilit:

• Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade
  Clinical Pharmacology & Therapeutics, 1984
• The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
  British Journal of Clinical Pharmacology, 1984
• Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism
  Biochemistry, 1984
• INTERACTIONS OF DRUGS ACTIVE AT OPIATE RECEPTORS AND DRUGS ACTIVE AT α₂‐RECEPTORS ON VARIOUS TEST SYSTEMS
  British Journal of Pharmacology, 1982
• An Automated HPLC Method for the Assay of Propranolol and Its Basic Metabolites in Plasma and Urine
  Journal of Chromatographic Science, 1982
• Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists.
  Published by Wiley ,1981
• Inhibition of oxidative drug metabolism by beta‐adrenoceptor antagonists in related to their lipid solubility [letter]
  British Journal of Clinical Pharmacology, 1981
• Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.
  Published by Wiley ,1981
• Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens.
  Published by Wiley ,1980
• Biological fate of butylated hydroxytoluene (BHT); Binding in vitro of BHT to liver microsomes.
  CHEMICAL & PHARMACEUTICAL BULLETIN, 1979